Paxlovid
Active Pharmaceutical Ingredients 2025-03-03
English Synonyms Nirmatrelvir PF-07321332 (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
Catalog ID101225
CAS NO.2628280-40-8
Purity 95%
MDL NumberMFCD34473213
EINEC Molecular FormulaC23H32F3N5O4
Molecular Weight499.531
| Category | Content |
|---|---|
| Generic Name | Paxlovid (Nirmatrelvir/Ritonavir) |
| Brand Name | Paxlovid |
| Drug Class | Antiviral (Protease Inhibitor Combination) |
| Mechanism of Action | Paxlovid is a combination of nirmatrelvir and ritonavir. Nirmatrelvir is a reversible covalent peptidomimetic inhibitor of the main protease (Mpro) of SARS-CoV-2, which is crucial for viral replication. Ritonavir acts as a pharmacokinetic enhancer by inhibiting the cytochrome CYP3A4 enzyme, thereby increasing the half-life and bioavailability of nirmatrelvir. |
| Indications | Treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease, within 5 days of symptom onset. |
| Dosage Forms | Tablet (Nirmatrelvir 150 mg, Ritonavir 100 mg) |
| Administration | Oral, twice daily for 5 days. |
| Side Effects | Common side effects include altered taste, diarrhea, and hypertension. |
| Developer | Pfizer |
| Approval Date | Emergency use authorization granted in 2021 |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
